Best of ASCO - 2014 Annual Meeting

 

Welcome

Germ Cell/Testicular

Genitourinary (Nonprostate) Cancer

2018 ASCO Annual Meeting

Sort by: title abstract no. first author
ABSTRACT TITLEFIRST AUTHORABSTRACT NO.
A pilot study to assess the accuracy of “intuition” in analyzing post chemotherapy (chemo) residual retroperitoneal (RP) masses in patients (pts) with non seminomatous germ cell tumor (NSCGCT).

Clint Cary

e16535

Adjuvant etoposide plus cisplatin (EP) for pathologic stage (PS) II nonseminomatous germ cell tumor (NSGCT).

Deaglan Joseph McHugh

4552

Apache: An open label, randomized, phase 2 study of durvalumab (Durva), alone or in combination with tremelimumab (Treme), in patients (pts) with advanced germ cell tumors (GCT): Results at the end of first stage.

Daniele Raggi

4547

Bleomycin-induced pulmonary toxicity: A retrospective review of incidence and risk factors.

Pritam Tayshetye

e16532

Circulating miR-371a-3p for the detection of low volume viable germ cell tumor: Expanded pilot data, clinical implications and future study.

Lucia Nappi

4549

Clinical utility of plasma miR-371a-3p in testicular germ cell tumors.

Michal Mego

e16540

Clinicohistopathological features and treatment outcomes in testicular lymphomas: A single center experience.

Ali Murat Sedef

e16533

Comprehensive genomic characterization of chemotherapy-resistant testicular germ cell tumors (TGCT).

Andrea Necchi

4555

Emergency etoposide-cisplatin (Em-EP) for patients with germ cell tumors (GCT) and trophoblastic neoplasia (TN).

Charleen Chan Wah Hak

e16539

Etoposide and cisplatin (EP) for metastatic good-risk germ cell tumors (GCTs): The Memorial Sloan-Kettering Cancer Center (MSKCC) experience in 944 patients (pts).

Samuel Funt

4550

Multicenter randomized phase 2 trial of paclitaxel, ifosfamide, and cisplatin (TIP) versus bleomycin, etoposide, and cisplatin (BEP) for first-line treatment of patients (pts) with intermediate- or poor-risk germ cell tumors (GCT).

Darren R. Feldman

4508

Non-germ cell testicular tumours: Follow-up and outcomes—A literature review and experience from a UK tertiary referral centre over 13 years.

Louisa Scott

e16536

P3BEP (ANZUP 1302): An international randomised phase 3 trial of accelerated versus standard BEP chemotherapy for adult and paediatric male and female patients with intermediate and poor-risk metastatic germ cell tumours (GCTs).

Peter S. Grimison

TPS4596

Patterns of care and outcome of germ cell tumours (GCT) in an Australian high-volume centre.

Malmaruha Arasaratnam

e16534

Performance status (PS) in advanced germ cell tumors (aGCT): Clinical and prognostic value of an underreported important variable.

Vitor Fiorin de Vasconcellos

e16537

Psychological stress in long-term survivors of testicular cancer: A Danish nationwide cohort study.

Michael Kreiberg

4554

Retroperitoneal cancer viability after postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) in good risk germ cell tumors (GCTs).

Fadi Taza

4551

Safety and tolerability of guadecitabine (SGI-110) plus cisplatin in patients (pts) with platinum-refractory germ cell tumors (GCT): Preliminary results from an open label phase 1b study.

Neda Hashemi-Sadraei

e16545

Ten year overview of germ cell tumours treated within the Anglian Germ Cell Cancer Collaborative Group (AGCCCG) (2005-2015): Outcomes and the impact of specialist multidisciplinary review on decision making.

Constantine Alifrangis

e16538

Testicular germ cell tumors with malignant somatic component: A single-center experience.

Caleb Scheckel

e16544

The prognostic value of teratoma in the primary tumor and postchemotherapy retroperitoneal lymph node dissection (PC-RPLND) specimens in patients with germ cell tumors (GCTs).

Fadi Taza

4553

Understanding the molecular and genomic differences between primary germ cell tumors and late relapse.

Aabha Oza

e16542

Use of 18F-FDG PET/CT to select candidates for active surveillance: Results of the SEMITEP trial of PET-directed strategy for stage 1 seminoma.

Yohann Loriot

4548